Stereotactic body radiation therapy for oligometastatic renal cell carcinoma: improving outcomes in an otherwise radioresistant malignancy
Franzese et al. recently analyzed the outcomes of patients treated at their institution with stereotactic body radiation therapy (SBRT) for oligometastatic renal cell carcinoma (RCC) (1). They reported a 2-year survival rate from SBRT of 100% and excellent local control with very few toxicities. As we place their findings into the context of overall management of metastatic RCC (mRCC), a number of points warrant discussion.